NCT01331109 - Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Primary Fibromyalgia

Interventions

DRUG

Milnacipran

maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.

Trial Locations (31)

27103

Forest Investigative Site 052, Winston-Salem

27612

Forest Investigative Site 062, Raleigh

29650

Forest Investigative Site 046, Greer

30513

Forest Investigative Site 058, Blue Ridge

33409

Forest Investigative Site 055, West Palm Beach

34609

Forest Investigative Site 014, Spring Hill

35205

Forest Investigative Site 040, Birmingham

40202

Forest Investigative Site 017, Louisville

45219

Forest Investigative Site 016, Cincinnati

45432

Forest Investigative Site 015, Dayton

48104

Forest Investigative Site 009, Ann Arbor

48307

Forest Investigative Site 024, Rochester Hills

49127

Forest Investigative Site 036, Stevensville

53406

Forest Investigative Site 004, Racine

61614

Forest Investigative Site 010, Peoria

78215

Forest Investigative Site 003, San Antonio

78258

Forest Investigative Site 042, San Antonio

78732

Forest Investigative Site 023, Austin

80907

Forest Investigative Site 034, Colorado Springs

84015

Forest Investigative Site 025, Clinton

84102

Forest Investigative Site 013, Salt Lake City

86442

Forest Investigative Site 033, Bullhead City

87109

Forest Investigative Site 018, Albuquerque

92868

Forest Investigative Site 035, Orange

Forest Investigative Site 053, Orange

93710

Forest Investigative Site 012, Fresno

93720

Forest Investigative Site 045, Fresno

93721

Forest Investigative Site 051, Fresno

95825

Forest Investigative Site 050, Sacramento

98104

Forest Investigative Site 063, Seattle

08889

Forest Investigative Site 049, Whitehouse Station